Stromal cell derived factor-1 and long-term prognosis in acute coronary syndrome

Biomark Med. 2019 Oct;13(14):1187-1198. doi: 10.2217/bmm-2019-0133. Epub 2019 Sep 27.

Abstract

Aim: To explore long-term prognostic value of SDF-1 in acute coronary syndrome (ACS). Materials & methods: We included 254 patients with ACS. Plasma SDF-1 was measured and patients were classified into tertiles of SDF-1. Results: Multivariate analysis showed third tertile of SDF-1 as an independent predictor of all-cause death (HR: 2.5; 95% CI: 1.2-5.2; p = 0.011) and the composite of major adverse cardiovascular and cerebrovascular events (HR: 1.8; 95% CI: 1.1-3.1; p = 0.031). SDF-1 added to a clinical model can improve all-cause death prediction (net reclassification improvement 0.362; 95% CI: 0.423-0.681; p = 0.027). Conclusion: SDF-1 is an independent predictor of all-cause mortality and major adverse cardiovascular and cerebrovascular events in long-term follow-up of patients with ACS and adds prognostic information beyond traditional cardiovascular risks factors.

Keywords: NSTEMI; STEMI; acute coronary syndrome; biomarker; heart failure; long-term; myocardial infarction; prognosis; stromal cell derived factor-1; unstable angina.

MeSH terms

  • Acute Coronary Syndrome / blood*
  • Acute Coronary Syndrome / diagnosis*
  • Acute Coronary Syndrome / mortality
  • Aged
  • Chemokine CXCL12 / blood*
  • Endpoint Determination
  • Female
  • Humans
  • Male
  • Middle Aged
  • Prognosis
  • ROC Curve
  • Risk Assessment

Substances

  • CXCL12 protein, human
  • Chemokine CXCL12